Thermo Fisher Scientific Inc. (0R0H)
London Exchange · UK · prices in USD · close of 23 Oct 2026
Key indicators
| Last close | USD 670.88 |
|---|---|
| 52-week range | 434.58 – 705.96 |
| Return, 1 month / 3 months | +1.8% / +16.9% |
| Return, 1 year / 3 years | +17.8% / +43.8% |
| Trend | Uptrend |
| RSI (14) | 53 |
| Volatility (1 year) | 28.8% |
| Worst drawdown (1 year) | -31.4% |
| Average daily value traded | 1.84M USD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Thermo Fisher Scientific is a scientific instruments and laboratory supplies company based in the United States. It makes analytical instruments, laboratory equipment, reagents and consumables, and it provides specialty diagnostics and life sciences products and services. Its customers include pharmaceutical and biotechnology companies, hospitals and healthcare providers, universities and research institutions, and government agencies around the world. The company supports scientific research, clinical diagnosis and the development and production of medicines and other products.
On this site Thermo Fisher Scientific Inc. appears as a stock on the London Exchange (UK), code 0R0H, with prices in US dollars (USD). Our dividend records, which start in 2019, show payments in 4 different calendar years. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Thermo Fisher Scientific Inc. (0R0H) trades on the London Exchange in UK. It last closed at USD 670.88 on 23 October 2026.
Its price-based Market X-Ray is 73 out of 100 (a strong price profile), ranking 382 of 3,787 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price rose 17.8% and over the last three months it rose 16.9%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on London Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 89 · Strong | Trading above its long-term averages and near its highs. | |
| Above 200-day average | 22.0% | ||
| From 52-week high | -3.5% | ||
| Momentum | 81 · Strong | Rising faster than most stocks on this exchange. | |
| 3-month return | 16.9% | ||
| 6-month return | 43.0% | ||
| 12-month return, skipping the last month | 15.7% | ||
| Stability (higher is calmer) | 56 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 28.8% | ||
| Worst drawdown, 1 year (smaller is calmer) | -31.4% | ||
| Liquidity | 59 · Fair | Moderate trading activity. | |
| Average daily value traded | 1.84M USD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 2 |
Strengths
- Trend: Trading above its long-term averages and near its highs.
- Momentum: Rising faster than most stocks on this exchange.
Weak spots
No lens is weak against its exchange.
Returns
| 1 week | −2.5% |
|---|---|
| 1 month | +1.8% |
| 3 months | +16.9% |
| 6 months | +43.0% |
| 1 year | +17.8% |
| 3 years | +43.8% |
| 5 years | +10.3% |
Signals
| 50-day / 200-day average | 644.65 / 549.68 |
|---|---|
| Golden / death cross (60 days) | Golden, 46 days ago |
| New 52-week high | Yes |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 27.13 |
Technical summary
Recent dividends
| Ex-dividend date | Amount per share |
|---|---|
| 14 Sep 2022 | USD 0.3000 |
| 14 Jun 2022 | USD 0.3000 |
| 15 Mar 2022 | USD 0.3000 |
| 14 Dec 2021 | USD 0.2600 |
| 14 Sep 2021 | USD 0.2600 |
| 14 Jun 2021 | USD 0.2600 |
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on London Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.